IP Verse

Deciphera Pharmaceuticals competitive analysis

Latest publications and patents of Deciphera Pharmaceuticals New

Explore the latest publications and patents granted to Deciphera Pharmaceuticals, showcasing their recent innovations and technological advancements.

Last updated on: Sep 27, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Deciphera Pharmaceuticals

EP4084779
Oct 9, 2024Compositions Of 1-(4-Bromo-5-(1-Ethyl-7-(Methylamino)-2-Oxo-1,2-Dihydro-1,6-Naphthyridin-3-Yl)-2-Fluorophenyl)-3-PhenylureaGranted And Under Opposition
EP4084778
Nov 1, 2023Amorphous Kinase Inhibitor Formulations And Methods Of Use ThereofGranted And Under Opposition

Latest oppositions filed by Deciphera Pharmaceuticals

Explore patent oppositions filed by Deciphera Pharmaceuticals against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 2, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3632907
N-(Azaaryl)Cyclolactam-1-Carboxamide Derivative, Preparation Method Therefor, And Use ThereofABBISKO THERAPEUTICSNov 13, 2024

Latest patents of Deciphera Pharmaceuticals opposed by its competitors

Explore Deciphera Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 2, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP4084779
Oct 9, 2024Compositions Of 1-(4-Bromo-5-(1-Ethyl-7-(Methylamino)-2-Oxo-1,2-Dihydro-1,6-Naphthyridin-3-Yl)-2-Fluorophenyl)-3-Phenylurea1
EP4084778
Nov 1, 2023Amorphous Kinase Inhibitor Formulations And Methods Of Use Thereof1

Latest PTAB cases involving Deciphera Pharmaceuticals

Discover the latest PTAB cases involving Deciphera Pharmaceuticals, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Deciphera Pharmaceuticals with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
DECIPHERA PHARMACEUTICALS12 - - Balanced
ABBISKO THERAPEUTICS - 1 - - Non-Active
ALFRED E TIEFENBACHER443 - - Highly Aggressive